PlainPharmaWatch

CMS Open Payments · Program Year 2024

BioCryst US Sales Co., LLC

BioCryst US Sales Co., LLC reported $658,195.86 across General Payments, Research, and Ownership to 6,409 physicians and teaching hospitals across 6,409 transactions.

See the rankings → How this is sourced
$658.2K
All-tracks total
6,409
Transactions
6,409
Recipients
−$10.0K
General Payments vs PY2023

BioCryst US Sales Co., LLC reported $658,195.86 across all CMS Open Payments tracks (General + Research + Ownership) to 6,409 physicians and teaching hospitals in Program Year 2024 - ranking #705 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $658,195.86, averaging $102.70 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer biocryst-us-sales-co-llc BioCryst US Sales Co., LLC

$658.2K · #705/1,925 · 0.0% industry · PY2024

  • TOT $658.2K
  • RANK #705
  • SHARE 0.0%
  • TXN 6,409
  • RCP 6,409
  • CAT 7
  • GEN $658.2K
  • ΔGEN −$10.0K
  • TOP1 10.4%
  • PY 2024

Volume peers

Nearest volume peer: Xtant Medical Inc ($659.3K)

Xtant Medical Inc$659.3KBioCryst US Sales Co., LLC (…$658.2KEnterra Medical, Inc.$656.0KFusion Orthopedics USA, LLC$655.1KSeigla Medical, Inc.$651.1K
All-tracks payment totals near BioCryst US Sales Co., LLC (CMS Open Payments PY2024)

BioCryst US Sales Co., LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

BioCryst US Sales Co., LLC's CMS-reported General Payments decreased by $10.0K (−1.5%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: BIOCRYST US SALES CO., LLCPY2023: BIOCRYST US SALES CO., LLCPY2024: BioCryst US Sales Co., LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$668.2KPY2024$658.2K
PY2023
$668,158.53
PY2024
$658,195.86

What the Data Shows for BioCryst US Sales Co., LLC

$658,195.86: that is what BioCryst US Sales Co., LLC reported in payments to 6,409 physicians and teaching hospitals during Program Year 2024, spread across 6,409 transactions ($102.70 per transaction, $102.70 per recipient). The company sits at rank #705 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

Of the 7 general-payment categories charted below, "Compensation for Services Other Than Consulting" is the largest at $294.9K across 86 transactions, 44.8% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

BioCryst US Sales Co., LLC made 7 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $294.9K, 44.8% of General Payments.

BioCryst US Sales Co., LLC reports 7 general-payment categories - the top three are Compensation for Services Other Than Consulting (44.8%), Food and Beverage (23.7%), and Consulting Fee (18.0%). The remaining 4 categories make up 13.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How BioCryst US Sales Co., LLC divides its payments

Ranked by total dollars reported per category

1. Compensation for Services…$294.9K2. Food and Beverage$155.8K3. Consulting Fee$118.3K4. Travel and Lodging$49.7K5. Grant$29.7K6. Space Rental or Facility …$9.1K7. Education$607.99
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $294.9K 86
Food and Beverage $155.8K 6,115
Consulting Fee $118.3K 33
Travel and Lodging $49.7K 117
Grant $29.7K 3
Space Rental or Facility Fees $9.1K 6
Education $607.99 49

Recipient Concentration in General Payments

The five largest recipient relationships account for $234,293.91 (35.6%) of $658,195.86 in this company's General Payments records across 2,052 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for BioCryst US Sales Co., LLC

The five named recipients with the highest reported General Payments from this company

Raffi Tachdjian$68.4KWilliam Lumry$62.6KPatricia Stewart$49.7KJeffrey Rumbyrt$27.5KDonald Levy$26.1K
  1. 1

    Raffi Tachdjian

    $68,423.21 across 58 reported transactions

  2. 2

    William Lumry

    $62,597.33 across 32 reported transactions

  3. 3

    Patricia Stewart

    $49,671.68 across 41 reported transactions

  4. 4

    Jeffrey Rumbyrt

    $27,480.38 across 31 reported transactions

  5. 5

    Donald Levy

    $26,121.31 across 34 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as BioCryst US Sales Co., LLC's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about BioCryst US Sales Co., LLC.

Gynesonics, Inc.

HHI 375

CDC Medical LLC

HHI 376

Carl Zeiss Meditec, Inc.

HHI 376

Janssen Research & Development, LLC

HHI 372

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with BioCryst US Sales Co., LLC.

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download BioCryst US Sales Co., LLC's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.